MedTrace Logo

Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer

NCT00349557 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2014-07-16

No results posted yet for this study

Summary

The purpose of this study is to determine the acute and late toxicities from radiation therapy in combination with bevacizumab (given every 2 weeks for 16 weeks then every 3 weeks for 12 weeks), bicalutamide (every day for 16 weeks) and goserelin (every 3 months for 2 years).

Conditions

Interventions

DRUG

bevacizumab, bicalutamide and goserelin

PROCEDURE

intensity modulated radiation therapy (IMRT)

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Benaroya Research Institute

    lead OTHER

Principal Investigators

  • Jacqueline Vuky, MD · Virginia Mason Medical Center

  • Huong Pham, MD · Virginia Mason Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00349557 on ClinicalTrials.gov